Tectonic reports early safety data for vascular-disease antibody
Tectonic Therapeutic ($TECX) reported favorable Phase Ia safety findings for TX2100, an experimental antibody being developed for hereditary hemorrhagic telangiectasia, an inherited vascular disorder. Across six single-dose cohorts in healthy volunteers, adverse events were described as transient and mild or moderate, with no deaths, serious adverse events or severe treatment-emergent events. Anti-drug-antibody results remain pending. The findings support selecting doses for patient studies but
0